Showing results (1491-1500 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|May 23, 2014
A cost-effectiveness study of intravenous immunoglobulin in childhood idiopathic thrombocytopenia purpura patients with life-threatening bleedingRosarin Sruamsiri, Piyameth Dilokthornsakul, Chayanin Pratoomsoot, et al.
Pharmacoeconomics|April 9, 2015
Characterizing Heterogeneity Bias in Cohort-Based ModelsElamin H Elbasha, Jagpreet Chhatwal
Pharmacoeconomics|August 1, 2020
Incorporating Pharmacometrics into Pharmacoeconomic Models: Applications from Drug DevelopmentMeenakshi Srinivasan, Annesha White, Ayyappa Chaturvedula, et al.
Pharmacoeconomics|January 21, 2014
Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapseMichael Adena, Jennifer Houltram, Stephen P Mulligan, et al.
Pharmacoeconomics|July 20, 2012
The state of health economic research in South Africa: a systematic reviewPaul Gavaza, Karen L Rascati, Abiola O Oladapo, et al.
Pharmacoeconomics|January 29, 2014
Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelinesJosephine Mauskopf, Miny Samuel, Doreen McBride, et al.
Pharmacoeconomics|October 12, 2012
Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic reviewAva John-Baptiste, Man Wah Yeung, Victoria Leung, et al.
Pharmacoeconomics|August 23, 2022
Are We Agreed? Self- Versus Proxy-Reporting of Paediatric Health-Related Quality of Life (HRQoL) Using Generic Preference-Based Measures: A Systematic Review and Meta-AnalysisDiana Khanna, Jyoti Khadka, Christine Mpundu-Kaambwa, et al.
Pharmacoeconomics|March 18, 2023
Economic Impact of Insufficient and Disturbed Sleep in the WorkplaceDanielle R Glick, Samuel A Abariga, Irine Thomas, et al.
Pharmacoeconomics|March 23, 2023
Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalGiovany Orozco Leal, Nigel Armstrong, Ashleigh Kernohan, et al.
Pageof 336